每经AI快讯，中国同辐(01763.HK)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港 元，成交额1302.97万港元。 ...

Core Viewpoint - China Tongru (01763) has seen its stock price increase by over 130% this year, with a recent rise of 7.94% to HKD 24.48, driven by significant developments in the nuclear medicine sector [1] Group 1: Company Developments - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - China Tongru has launched carbon isotope products, marking a breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has officially initiated the construction of the second phase of its stable isotope base project, positioning itself as a leader in the complete industrial chain of breath test products [1] Group 2: Industry Insights - The approval of Pluvicto is anticipated to further ignite interest in the domestic nuclear medicine sector, with diagnostic nuclear drugs expected to see increased demand alongside therapeutic drugs [1] - Analysts suggest focusing on companies like China Tongru that are leading in the development of new isotopes and new targets within the nuclear medicine space [1]

Group 1 - China Tongru (01763) has seen its stock price increase by over 130% year-to-date, with a recent rise of 7.94% to HKD 24.48, and a trading volume of HKD 13.03 million [1] - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - Ping An Securities highlighted that the approval of Pluvicto may further ignite interest in the domestic nuclear medicine sector, suggesting to pay attention to companies like China Tongru that are leading in new isotopes and targets [1] Group 2 - On October 31, China Tongru announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has become a leading enterprise that fully masters the entire industry chain of breath test products and has officially initiated the construction of the second phase of its stable isotope base project [1]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [30]. Core Insights - Novartis' radioligand therapy drug Pluvicto has received approval for two indications in China, which is expected to boost the domestic nuclear medicine industry [3]. - BeiGene has raised its revenue guidance for 2025, now expecting between RMB 362 billion and RMB 381 billion, driven by strong product sales and improved operational efficiency [3]. Summary by Sections Industry Overview - Novartis' Pluvicto is approved for treating specific types of prostate cancer, with projected sales of USD 1.389 billion (approximately RMB 9.9 billion) for the first three quarters of 2025 [3]. - The approval of Pluvicto is anticipated to stimulate growth in the nuclear medicine sector, with a focus on companies leading in new isotopes and targets, such as Dongcheng Pharmaceutical and Yunnan Baiyao [3]. Company Performance - BeiGene's revenue for the first three quarters of 2025 reached RMB 275.95 billion, a year-on-year increase of 44.2%, surpassing the total revenue of RMB 272.1 billion for the previous year [3]. - The company has adjusted its 2025 revenue guidance upwards due to strong growth from its leading product, Brukinsa (Zebutinib), in the U.S. market and ongoing expansion in Europe and other key markets [3]. Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as Heng Rui Medicine and BeiGene, as well as those with high potential single products like Yipin Hong and Sanofi [5]. - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as Dongcheng Pharmaceutical and Yuanda Medicine [5].

Core Insights - As of November 10, a total of 108 stocks reached their 52-week highs, with notable performers including Taijin Holdings (08321), OKURA HOLDINGS (01655), and Hejia Holdings (00704) achieving high rates of 125.00%, 84.90%, and 53.57% respectively [1] Summary by Category 52-Week Highs - Taijin Holdings (08321) closed at 0.620 with a peak price of 0.900, marking a 125.00% increase - OKURA HOLDINGS (01655) reached a closing price of 0.280 and a high of 0.355, reflecting an 84.90% rise - Hejia Holdings (00704) had a closing price of 0.345 and a peak of 0.430, showing a 53.57% increase - Other notable stocks include Sanhe Chemical (00301) with a 41.67% increase and Aide New Energy (02623) with a 36.25% rise [1] 52-Week Lows - Wangshan Wangshui-B (02630) recorded a closing price of 52.850 and a low of 51.000, resulting in a -21.84% decrease - Eight Horses Tea (06980) had a closing price of 52.850 and a low of 51.100, reflecting a -10.98% decline - New Enjoy Times (08519) reached a low of 0.270, marking a -10.00% drop - Other significant declines include Jiujiang Bank (06190) at -8.99% and Kun Group (00924) at -6.98% [3][4]

Core Viewpoint - China Tongru (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the title of "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [13C/14C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the niche field of urea [13C] and [14C] breath diagnostics [1] - The urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers in China and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Dongfang (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Pharmaceutical Industry Single Champion" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - The company focuses on the application of medical isotopes in the niche market of Urea [13C] and [14C] breath diagnostics [1] - The Urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers domestically and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Tongru (01763.HK) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the urea [C] and [C] breath diagnostic niche, producing products used for detecting Helicobacter pylori [1] - The company's urea [C] and [C] breath test products cover over 20,000 end customers in China and are sold to 90 countries and regions, maintaining a leading market share in the industry for several consecutive years [1] Industry Summary - The company aims to further strengthen its position in technological innovation, continuously delve into breath diagnostics and related fields, and develop more advanced products and solutions to meet clinical needs, contributing to the health defense of the population [1]

本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻呼氣診斷產品榮獲國家級製藥業單項冠軍 本公司董事會（「董事會」）欣然宣佈，近日，中國同輻附屬公司深圳市中核海得威 生物科技有限公司憑藉核心產品「尿素[13C/14C]呼氣試驗藥盒」成功入選國家級製 造企業並榮獲「製藥業單項冠軍」。 中國同輻始終聚焦於醫用同位素應用中的尿素[13C]及[14C]呼氣診斷細分領域，生 產的尿素[13C]及[14C]呼氣試驗產品用於檢測幽門螺旋桿菌，產品覆蓋國內2萬餘 家終端客戶，銷往90個國家和地區，市場佔有率連續多年穩居行業前列。 中國同輻將進一步強化科技創新主體地位，持續深耕 ...

Core Viewpoint - China Tongru (01763.HK) experienced a significant increase in stock price, rising over 10% in the afternoon trading session, indicating strong market interest and potential investor confidence [1] Group 1 - The stock price of China Tongru rose by 10.21%, reaching HKD 20.94 [1] - The trading volume for China Tongru was reported at HKD 24.42 million [1]